An Alzheimer’s Drug That Doesn’t Treat Alzheimer’s?

The video discusses AD Buchanumab, a drug approved by the FDA to target amyloid plaques in Alzheimer's patients. Despite its approval, the drug's effectiveness in improving cognitive symptoms is questioned. The amyloid hypothesis, which suggests plaques cause Alzheimer's, is explored alongside genetic factors. The video highlights the challenges in treating Alzheimer's and the controversy surrounding AD Buchanumab's approval. It also examines alternative research avenues, including Tau protein, inflammation, and gene therapy, as potential future directions for Alzheimer's treatment.

What new insight or understanding did you gain from this video?